{
    "clinical_study": {
        "@rank": "18179", 
        "acronym": "LENEA", 
        "brief_summary": {
            "textblock": "The LENEA study is an international, prospective, open label, non-randomized multicenter\n      clinical research study designed to assess the safety and effectiveness of the NANO LV lead\n      system."
        }, 
        "brief_title": "Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation (LENEA)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "LV Lead", 
            "LV Therapy", 
            "LV Treatment", 
            "LV Microcable"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Approved indication per ACC/AHA/HRS guidelines for implantation of a CRT-D system for\n             treatment of heart failure or life threatening ventricular tachyarrhythmia(s)\n\n          -  Receiving a new implant OR undergoing an upgrade from an existing ICD or pacemaker\n             implant with no prior implanted LV lead  OR undergoing a  new LV implant attempt\n             consecutive to a recent LV lead placement failure not related to coronary sinus\n             cannulation failure\n\n          -  Patient receiving the PARADYM RF CRT or PARADYM RF CRT SONR devices\n\n          -  Ability to provide informed consent for study participation and is willing and able\n             to comply with the prescribed follow-up tests and schedule of evaluations\n\n        Exclusion Criteria:\n\n          -  Ventricular tachyarrhythmia of transient or reversible causes such as acute\n             myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte\n             imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;\n\n          -  Incessant Ventricular tachyarrhythmias;\n\n          -  Unstable angina, or acute MI , CABG , or PTCA  within the past 4 weeks;\n\n          -  Correctable valvular disease that is the primary cause of heart failure;\n\n          -  Post heart transplant (patients who are waiting for a heart transplant are allowed in\n             the study);\n\n          -  Patient who had previously a permanently implanted LV lead;\n\n          -  Concurrent implant with another pacemaker or ICD (previously implanted pacemaker or\n             ICD devices should be removed prior to implant with the Paradym RF CRT-D or Paradym\n             RF CRT SONR);\n\n          -  Already included in another clinical study that could confound the results of this\n             study;\n\n          -  Life expectancy less than 1 year."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731210", 
            "org_study_id": "LCNA02 - LENEA"
        }, 
        "intervention": {
            "intervention_name": "implantation of the new LV lead: NANO system.", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 20, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rouen", 
                    "country": "France", 
                    "zip": "76000"
                }, 
                "name": "CHU Charles Nicolle"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation", 
        "overall_contact": {
            "email": "frederic.anselme@chu-rouen.fr", 
            "last_name": "Fr\u00e9d\u00e9ric Mr ANSELME, MD", 
            "phone": "+ 33 (0)2 32 88 86 25"
        }, 
        "overall_contact_backup": {
            "email": "ghislaine.gestin@sorin.com", 
            "last_name": "Ghislaine Mrs GESTIN", 
            "phone": "+33 1 46 01 36 06"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: National agency of health and medecine", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Spain: ministery of health", 
                "Italy: ministery of health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Freedom from left ventricular lead related complications through 1 month", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731210"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sorin Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sorin Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}